Protective effect of caffeine in Parkinson's disease: Systematic review
DOI:
https://doi.org/10.24054/rcsf.v9i1.2436Keywords:
Parkinson's disease, Caffeine, neuroprotectiveAbstract
INTRODUCTION: Parkinson's disease is characterized by the loss of pigmented dopaminergic neurons of the para compacta of the substantia nigra, which provide dopaminergic innervation to the striatum. These two structures are part of the basal ganglia. For the typical symptoms of the disease to begin to manifest, there must be a neuronal loss of at least 80%. Many studies have established the relationship between Parkinson's and caffeine, mainly because caffeine acts on A2 adenosine receptors in D2 dopaminergic neurons present in the substantia nigra, demonstrating its neuroprotective effect. METHODS: A systematic review was carried out in PubMed, a reliable and specialized database in health sciences, in which quantitative reviews of the consumption or administration of caffeine and its protective effect in Parkinson's disease were sought from the year 2013 to the year 2023. RESULTS: Of the total articles selected for our study, 2 groups were disaggregated, the first group contemplates a sample of patients diagnosed with PD in an early stage and the second is based on a sample of patients diagnosed with PD in a late stage. the association of both groups was analyzed by means of a forest diagram. CONCLUSION: The systematic review and each one of the articles considered for the execution of this work support the original hypothesis that coffee does have protective effects in Parkinson's disease, indicating that coffee is an effective treatment.
Downloads
References
Vargas-Barahona, L. M. (2007). Enfermedad de Parkinson y la Dopamina. Bun Synapsis, 2(2), 11-15.
Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease. Mov Disord. 2022 Apr;37(4):853-857. doi: 10.1002/mds.28897. Epub 2022 Jan 9. PMID: 35001424; PMCID: Efecto protector de la cafeína en la Enfermedad de Parkinson. [Nutrición y Dietetical], [(2023)] |7 PMC9306703.
Ishibashi, K. (2022). La cafeína y los antagonistas de los receptores A2A de la adenosina como posibles adyuvantes de la terapia anticolinérgica en la enfermedad de Parkinson. Obtenido de Rev.Biomed.
Saavedra Moreno, J. S., Millán, P. A., & Buriticá Henao, O. F. (2019). Introducción, epidemiología ydiagnóstico de la enfermedad de Parkinson. Acta neurológica colombiana, 35, 2-10.
OMS. (2022). Organización mundial de la salud. Obtenido de https://www.who.int/es/news-room/factsheets/detail/parkinson-disease.
Wills AM, EberlyS, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA; Parkinson Study Group. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013 Mar;28(3):380-3. Doi: 10.1002/mds.25319. Epub2013 Jan 21. PMID: 23339054; PMCID: PMC3608707.
Gatto EM, Melcon C, Parisi VL, Bartoloni L, GonzálezCD. Inverse association between yerba mate consumption and idiopathic Parkinson's disease. A case-control study. J Neurol Sci. 2015 Sep 15;356(1-2):163-7. Doi: 10.1016/j.jns.2015.06.043. Epub 2015 Jun 24. PMID: 26148934.
Medeiros MS, Schumacher-Schuh AF, Altmann V, Rieder CRM. A Case-Control Study of the Effects of Chimarrão (Ilex paraguariensis) and Coffee on Parkinson's Disease. Front Neurol. 2021 Mar 10;12:619535. Doi: 10.3389/fneur.2021.619535. PMID: 33776884; PMCID: PMC7988202.
Gigante AF, Asabella AN, Iliceto G, Martino T, Ferrari C, Defazio G, Rubini G. Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease. Neurol Sci. 2018 Mar;39(3):551-555. Doi: 10.1007/s10072-018-3253-1. Epub 2018 Jan 23. PMID: 29362953.
Kumar PM, Paing SS, Li H, Pavanni R, Yuen Y, Zhao Y, Tan EK. Differential effect of caffeine intake in subjects with genetic susceptibility to Parkinson's Disease. Sci Rep. 2015 Nov 2;5:15492. Doi: 10.1038/srep15492. PMID: 26522888; PMCID: PMC4629131.
Ojeda-López C, Cervantes-Arriaga A, Rodríguez-Violante M, Corona T. Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson's disease. Neurol Sci. 2013 Jun;34(6):979-83. Doi: 10.1007/s10072-012-1180-0. Epub 2012 Sep 7. PMID: 22955949.
Paul KC, Chuang YH, Shih IF, Keener A, Bordelon Y, Bronstein JM, Ritz B. The association between lifestyle factors and Parkinson's disease progression and mortality. Mov Disord. 2019 Jan;34(1):58-66. Doi: 10.1002/mds.27577. PMID: 30653734; PMCID: PMC6544143.
Sharma K, Fallon SJ, Davis T, Ankrett S, Munro G, Christopher G, Coulthard E. Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson's disease according to task demands. Psychopharmacology (Berl). 2022 Feb;239(2):605-619. Doi: 10.1007/s00213-021-06054-9. Epub 2022 Jan 10. PMID: 35006304; PMCID: PMC8799544.
Yamada-Fowler N, Fredrikson M, Söderkvist P. Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson's disease in Swedish population. PLoS One. 2014 Jun 10;9(6):e99294. Doi: 10.1371/journal.pone.0099294. PMID: 24915238; PMCID: PMC4051678.
Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA.Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. J Parkinsons Dis. 2020;10(2):505-510. Doi: 10.3233/JPD191882. PMID: 32250320; PMCID: PMC7416447.
Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003 Mar 11;60(5):790-5. Doi: 10.1212/01.wnl.0000046523.05125.87. PMID: 12629235.
Ishibashi K, Miura Y, Wagatsuma K, Toyohara J, Ishiwata K, Ishii K. Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease. Mov Disord. 2022 Apr;37(4):853-857. doi: 10.1002/mds.28897. Epub 2022 Jan 9. PMID: 35001424; PMCID: Efecto protector de la cafeína en la Enfermedad de Parkinson. [Nutrición y Dietetical], [(2023)] |7 PMC9306703.
Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction withCreatine. Clin Neuropharmacol. 2015 Sep-Oct;38(5):163-9. doi: 10.1097/WNF.0000000000000102. PMID: 26366971; PMCID: PMC4573899
Saavedra Moreno, J. S., Millán, P. A., & Buriticá Henao, O. F. (2019). Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta neurológica colombiana, 35, 2-10
Downloads
Published
Versions
- 2023-01-08 (2)
- 2023-08-08 (1)
How to Cite
Issue
Section
License
Copyright (c) 2023 REVISTA CIENTÍFICA SIGNOS FÓNICOS
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
